Hims(US:HIMS) Prnewswire·2025-06-27 13:01Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits following the termination of its collaboration with Novo Nordisk due to concerns over deceptive marketing practices related to the weight loss drug Wegovy® [1][2][4]. Group 1: Lawsuits and Allegations - The lawsuits, filed on June 25, 2025, seek to represent investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [1][3]. - Allegations include that Hims & Hers made false and misleading statements and failed to disclose critical information regarding the safety of its products and the legality of its marketing practices [4][5]. - The termination of the collaboration with Novo Nordisk was announced on June 23, 2025, citing concerns over illegal mass compounding and deceptive marketing practices that jeopardized patient safety [5]. Group 2: Impact on Share Price - Following the announcement of the termination, Hims & Hers shares experienced a significant decline, crashing by 30% [2]. Group 3: Investigation and Legal Support - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [3][6]. - The firm is also seeking information from individuals who may assist in the investigation, highlighting the potential for whistleblower rewards under the SEC Whistleblower program [6].